The 67th American Society of Hematology (ASH) Annual Meeting & Exposition will take place from December 6–9, 2025, in Orlando, Florida, offering both in-person and virtual participation. As the leading global forum for hematology, ASH 2025 will bring together clinicians, researchers, and industry experts to present the latest advances in blood cancer research, benign hematologic disorders, emerging therapies, and clinical practice standards. The meeting features high-impact scientific sessions, educational programs, late-breaking abstracts, and extensive industry exhibits, with core content available online and on-demand through early 2026, ensuring broad access for the international hematology community.
15 Posts Not to Miss from ASH 2025
In this article, we selected 15 key posts you shouldn’t miss, capturing the most impactful insights, research updates, and expert perspectives shared throughout ASH 2025.
“630am 250+ myeloma docs Standing room only, to the rafters.”
“ASH25 COBRA = big challenge to ENDURANCE, but no firm answers on KRd vs VRd since PI exposure different. Nevertheless – authors for clearly showing that K 56 1x weekly carries a punch and is manageable! Although no PFS ∆ in ASCT-ineligible, so mainly for younger pts (?)”
“Wow 2 institutions at 2 meetings in less than 2 months!! First Mayo at SNO show survival decreases when ALC is low in brain tumors. Now Harvard at ASH find the same that survival decreases in lymphoma when ALC is low. The light begins to shine that LYMPHOPENIA affects survival.”
“This is it people … you heard it first at ASH25 ELN MRD 205 guidelines are in press in Blood Portfolio Bad news: It’s more complicated than before… Good news: there’s an app for it https://eln-aml-mrd-2025.vercel.app”
“Congratulations Alkhouli Laila for receiving ASH25 Abstract Achievement Award! So proud of your accomplishments and the mentorship of Harry Lesmana and excited to see what’s next! ”
“ASH25 Safety data from Phase 1 KTX-1001 (MMSET/NSD2 inhibitor) in heavily pretx RRMM (n=40) @szusmani
– tolerable TEAE with low Tx DC rates (2.5%), reduced H3K36me2 at C2D1 marrow. Single agent activity esp in t(4;14) look promising for upcoming combinations with carf/mezi.”
“The future belongs to combinations—and T-cell engagers plus CELMoDs may be one of the most powerful pairings yet.”
“Thrilled to moderate PER MPN Session this year : PER MPN Cases and Conversations at ASH25 alongside my brilliant colleagues Dr. Angela Fleischman, Dr Beth Psaila & Elf Lab – great discussion & an enthusiastic audience Q&A session! ”
“I’d like to give a shoutout to our team from The James at ASH25 sharing our world-class hematology oncology science. We’re showing up in a big way, with 100+ presentations that exemplify how we’re redefining what is possible along the spectrum of BloodCancers. If you’ll be there, please find our experts and strike up a conversation. Our booth is 181 and our presentation schedule is in the link below. To give you an appetizer, it’s a chance to hear how James scientists are:
• Engineering the future: Reaching new frontiers of CAR T-cell therapy and A.I. to transform how we understand and treat blood cancers
• Targeting resistance: Leading clinical trials for novel inhibitors – such as next-generation BTK inhibitors – aimed at overcoming the most challenging cases of treatment resistance
• Pioneering precision: Learning how to better evaluate cancer risk and optimizing therapies to treat aggressive leukemias in vulnerable adults”
“Sitting here at ASH25 , I am blown away by the progress in myeloma in the 21st century. I never thought we could “cure” patients from MM in my lifetime. When I started in the field a quarter century ago, patients would be lucky to make it past 3 years post-diagnosis”
“ASH25 Subset analysis from VERONA trial presented by Dr. Garcia-Manero venetoclax plus AZA combination showed trend towards better response rate and OS in younger pt, high IPSS-R and high BM blast mdssm”
“I’m delighted to share two presentations from our group at ASH 2025, focused on improving the safety of CAR T-cell therapy (links in comment).
Oral Presentation — High-dose anakinra for refractory ICANS
Abstract 928
Presenter: Emily Liang, MD
Monday, December 8
2:45 PM – 4:15 PM EST
OCCC – Sunburst Room (W340)
Key findings:
Comprehensive benchmarking of outcomes in the largest cohort to date (N = 101), conducted in collaboration with Oregon Health & Science University.
Median ICANS resolution: 8 days.
– Significant neurologic improvement (≥2-grade ICANS reduction without additional ICANS-directed therapy) achieved in 44% of patients at 72 hours.
– Anti-tumor efficacy preserved (91% CR/PR at day +28).
– Identified potential point-of-care biomarkers associated with anakinra efficacy, including platelet count, ferritin, and fibrinogen.
Poster — Independent validation of ALC thresholds for motor/neurocognitive toxicity (MNT) risk after ciltacabtagene autoleucel
Abstract 4147
Presenter: Yein Jeon, MSc
Sunday, December 7
6:00 PM – 8:00 PM EST
OCCC – West Halls B3–B4
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities — Poster II
Key findings:
– Commonly used ALC thresholds (3,000 and 5,000/µL) demonstrated limited discrimination, with high false-positive rates and meaningful false-negative rates.
– Findings support the need to move beyond single-parameter thresholds for pre-emptive management.
– Introduced a new prognostic model — NEMO — integrating point-of-care variables beyond ALC (CRP, fibrinogen, platelets). NEMO outperforms ALC-only approaches.
– Additional analyses will be presented as an oral presentation at Annual Tandem Meeting of the ASTCT and CIBMTR in February 2026!”
“I love all the blood cells (the normal ones) but I have a particularly soft spots for neutrophils which protect us against infections ASH25”
“Delighted to highlight the numerous ASH25 presentations and sessions led by our outstanding Hematology Division faculty & trainees at the 67th Annual American Society of Hematology meeting starting tomorrow! Full list here: https://lnkd.in/gVEd3Z8g”
At ASH25, Anath Lionel, MD, PhD presented the results of our retrospective analysis on the impact of extranodal (EN) disease on the clinical outcomes of 522 lymphoma patients treated with CD19-targeted CAR T-cell therapy.
EN disease was associated with lower complete response rate after CAR T compared to those with only nodal disease or no evidence of disease.
Site-specific analysis revealed that lymphomatous involvement of the liver, peritoneum, or GI tract was significantly associated with lower overall survival in multivariable analysis.
Lower progression-free survival was also observed in patients with liver or peritoneal involvement.
These findings underscore the importance of systematic characterization of EN disease on baseline imaging to inform pre-CAR T risk stratification and potentially guide targeted interventions like bridging RT in high-risk patients.
Read the full abstract here: https://lnkd.in/eFyzYHJ6
Authors: Anath Lionel, Sushanth Gouni, Karan Chohan, Lei Feng, Charles Gaulin, Amrit Gonugunta, Victoria Chu, Zachary Hunzeker, James Hill, Turcin Saridogan, Michelly Abreu, Jaimole Varghese, Karla Ow, Minifrida Santiago1, Amy Ayers, Farzaneh Maadani, Maria Guillermo-Pacheco, Janet Torres, Sherry Adkins, Misha Hawkins, MSN, RN, OCN, Mark Hamilton, Fateeha Furqan, Ayushi Chauhan, Ranjit Nair, Chijioke Nze MD, MPH, Hun Lee, Preetesh Jain, Luis Malpica Castillo, Luis Fayad, Michael Wang, Dai Chihara, Swaminathan P iyer, Chitra Hosing, Jeremy Ramdial, Partow Kebriaei, Elizabeth Shpall, Jason Westin, MD MS FASCO, Christopher R. Flowers, MD, Susan Wu, Paolo Strati, Sattva Neelapu, Sairah Ahmed”
More posts about ASH 2025 on OncoDaily.
Written by Nare, Hovhannisyan, MD